What development phase is (S)-Remoxipride in?

(S)-Remoxipride is FDA-approved (marketed).

What is the generic name of (S)-Remoxipride?

REMOXIPRIDE is the generic (nonproprietary) name of (S)-Remoxipride.

Last reviewed 2026-04-20 · How we verify

(S)-Remoxipride (REMOXIPRIDE)

FDA-approved withdrawn Small molecule Quality 5/100

Remoxipride, a marketed drug by an unspecified company, binds to the Sigma non-opioid intracellular receptor 1, positioning it uniquely in the market. Its key strength lies in its distinct mechanism of action, differentiating it from competitors like amisulpride, which is patent-protected until March 10, 2031. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	REMOXIPRIDE
Drug class	remoxipride
Target	D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved
First approval	1990

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(S)-Remoxipride CI brief — competitive landscape report
(S)-Remoxipride updates RSS · CI watch RSS